Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0642-1895 · 1 trial · 1 indication
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0642-1895 | EXPERIMENTAL | Participants will be administered a single dose of NNC0537-1482 intravenously. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC0642-1895 intravenously. |
| Name | Type | Description |
|---|---|---|
| NNC0642-1895 | DRUG | NNC0642-1895 will be administered intravenously. |
| Placebo | DRUG | Placebo will be administered intravenously. |
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 18.5 to 29.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening * Consider...
NNC0642-1895 is an investigational small molecule medicine being developed by Novo Nordisk A/S. It is in Phase 1 clinical development and is being studied in healthy volunteers, not in patients with a specific disease. It has not been approved by the FDA and remains an experimental compound.
NNC0642-1895 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program evaluating the compound. No partner or licensing arrangement for this asset has been disclosed.
NNC0642-1895 is in Phase 1 development. One Phase 1 trial has been registered and is currently active, with no completed trials reported. The study is not yet recruiting participants. As a Phase 1 investigational drug, NNC0642-1895 has not received FDA approval.
NNC0642-1895 is being evaluated in a single registered Phase 1 trial, NCT07829406, titled "A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People." The trial is not yet recruiting, is planned to enroll 148 participants, and is being conducted in the United States.
The Phase 1 trial of NNC0642-1895, NCT07829406, is a randomized, double-blind, placebo-controlled study. It plans to enroll 148 healthy volunteers aged 18 years and older, with all sexes eligible. Participants are healthy volunteers rather than patients, and the study is being run at sites in the United States.